Understand the source comparison
Peptide Clinics Colorado Providers Services 2026: Comparison
Small-Batch Synthesis (Real Peptides model) Full amino-acid sequencing, batch-specific HPLC + MS reports Third-party verified, ≥98% purity Temperature-monitored cold packs, −20°C to 4°C maintained Laboratory research classification, cGMP-adjacent processes Hig
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Small-Batch Synthesis (Real Peptides model)
- Full amino-acid sequencing, batch-specific HPLC + MS reports
- Third-party verified, ≥98% purity
- Temperature-monitored cold packs, −20°C to 4°C maintained
- Laboratory research classification, cGMP-adjacent processes
- Highest traceability. Every batch auditable to raw materials. Ideal for controlled studies requiring verifiable peptide integrity.
- 503B Outsourcing Facilities
- Batch records per cGMP, retained samples
- In-house testing, FDA-inspected processes
- Required for sterile compounds
- FDA-registered, subject to biennial inspection
- Regulatory compliant for therapeutic use. Higher cost due to compliance overhead. Best for clinics needing patient-specific compounding.
- Bulk Overseas Distributors
- Generic COA (often months old, not batch-specific)
- Claimed purity without independent verification
- Ambient shipping, no cold chain
- Unregistered, high enforcement risk
- Lowest cost, highest risk. Purity claims unverifiable. Suitable only for non-critical applications where peptide integrity isn't measured.
- Domestic Repackagers
- Rely on manufacturer COA, no in-house synthesis
- Copy manufacturer claims, no third-party testing
- Variable. Often ambient
- State pharmacy board oversight (if registered)
- Mid-tier cost, mid-tier risk. No synthesis traceability. If the manufacturer's COA is inaccurate, the repackager has no ability to detect it.